Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EndoBARR: Bevacizumab, Atezolizumab and Rucaparib in Endometrial Carcinoma
NCT03694262Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Jul 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rucaparib, bevacizumab and atezolizumab in endometrial carcinoma and uterine carcinosarcoma (UCS), sponsored by Medical College of Wisconsin. Primary endpoints: Treatment Related Overall Response Rate at 44 months and Overall Response Rate up to 3 years. Started Jul 2019; status: completed.
02
Drugs
rucaparibbevacizumabatezolizumab
03
Conditions
endometrial carcinomauterine carcinosarcoma (UCS)
Beyond the preview
Go deeper on NCT03694262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694262.